RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: evaluating the multiple components of response
M. Kallieri (Chaidari, Greece), E. Zervas (Athens, Greece), E. Fouka (Thessaloniki, Greece), K. Porpodis (Thessaloniki, Greece), M. Hadji Mitrova (Thessaloniki, Greece), E. Tzortzaki (Heraklion, Greece), M. Makris (Chaidari, Greece), M. Ntakoula (Chaidari, Greece), A. Papaioannou (Chaidari, Greece), P. Lyberopoulos (Chaidari, Greece), K. Dimakou (Athens, Greece), S. Koukidou (Athens, Greece), S. Ampelioti (Athens, Greece), A. Papaporfyriou (Athens, Greece), K. Katsoulis (Thessaloniki, Greece), M. Kipourou (Thessaloniki, Greece), N. Rovina (Athens, Greece), K. Antoniou (Heraklion, Greece), S. Vittorakis (Chania, Greece), P. Bakakos (Athens, Greece), P. Steiropoulos (Alexandroupolis, Greece), K. Markopoulou (Thessaloniki, Greece), P. Avarlis (Kalamata, Greece), ?. Papanikolaou (Corfu, Greece), M. Markatos (Chania, Greece), E. Gaki (Trikala, Greece), K. Samitas (Athens, Greece), K. Glynos (Athens, Greece), S. Papiris (Chaidari, Greece), D. Papakosta (Thessaloniki, Greece), N. Tzanakis (Heraklion, Greece), M. Gaga (Athens, Greece), K. Kostikas (Ioannina, Greece), S. Loukides (Chaidari, Greece)
Source: International Congress 2022 – Asthma biologics in real life studies
Session: Asthma biologics in real life studies
Session type: Thematic Poster
Number: 2389
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Kallieri (Chaidari, Greece), E. Zervas (Athens, Greece), E. Fouka (Thessaloniki, Greece), K. Porpodis (Thessaloniki, Greece), M. Hadji Mitrova (Thessaloniki, Greece), E. Tzortzaki (Heraklion, Greece), M. Makris (Chaidari, Greece), M. Ntakoula (Chaidari, Greece), A. Papaioannou (Chaidari, Greece), P. Lyberopoulos (Chaidari, Greece), K. Dimakou (Athens, Greece), S. Koukidou (Athens, Greece), S. Ampelioti (Athens, Greece), A. Papaporfyriou (Athens, Greece), K. Katsoulis (Thessaloniki, Greece), M. Kipourou (Thessaloniki, Greece), N. Rovina (Athens, Greece), K. Antoniou (Heraklion, Greece), S. Vittorakis (Chania, Greece), P. Bakakos (Athens, Greece), P. Steiropoulos (Alexandroupolis, Greece), K. Markopoulou (Thessaloniki, Greece), P. Avarlis (Kalamata, Greece), ?. Papanikolaou (Corfu, Greece), M. Markatos (Chania, Greece), E. Gaki (Trikala, Greece), K. Samitas (Athens, Greece), K. Glynos (Athens, Greece), S. Papiris (Chaidari, Greece), D. Papakosta (Thessaloniki, Greece), N. Tzanakis (Heraklion, Greece), M. Gaga (Athens, Greece), K. Kostikas (Ioannina, Greece), S. Loukides (Chaidari, Greece). RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: evaluating the multiple components of response. 2389
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|